Prospective Multicenter Study on Clinical Application of Sonazoid in Breast Tumor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

181 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-15

Study Completion Date

2021-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of Sonazoid specific angiography and high mechanical index,the role of Sonazoid in the differential diagnosis of breast benign and malignant tumors was explored.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sonazoid Contrast-enhanced Ultrasound in Assessing Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer Patients.

NCT04657341

Ultrasound

UNKNOWN

Prospective Multicenter Study on Clinical Application of Sonazoid in Liver Tumor

NCT04563897

Ultrasound

UNKNOWN

ShearWave™ Elastography of Breast Lesions in Chinese Patients

NCT02226081

Breast Neoplasms

COMPLETED

A Prospective Multi-center Study on Using Sonazoid Diagnose Early Stage Endometrial Cancer

NCT04961775

Endometrial Carcinoma Stage I

UNKNOWN

Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Breast Nodules

NCT03887598

Breast Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is a prospective, multi-center study.With pathology as the gold standard, based on quantitative and qualitative analysis, Sonazoid-CEUS was compared with MRI to explore the diagnostic efficacy (accuracy, sensitivity and specificity) of Sonazoid-CEUS for breast tumor in different pathological types.

Investigators will also record the parameter information of imaging examination, pathological type of pathological examination and immunohistochemical index.Contrast-enhanced ultrasound includes lesion location, initial peak tumor volume, 1-minute tumor volume, 2-minute tumor volume, and 5-minute tumor volume, as well as the time for contrast enhancement, contrast agent clearance, and contrast agent clearance.Whether there is no enhancement area in the lesion after contrast enhancement, shape after contrast enhancement, edge after contrast enhancement, order of enhancement, uniformity of enhancement, intensity enhancement, pattern of enhancement, clear boundary after contrast enhancement, aspect ratio after contrast enhancement, etc.The magnetic field strength of the equipment is planned to be recorded in the enhanced MRI information, the name of the MRI contrast agent, the lesion location, the size of the LESION, and the scanning performance are enhanced (lump-like enhancement, non-lump-like enhancement, point-like enhancement), time-signal intensity enhancement curve, DWI signal, ADC value, etc.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ultrasound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Conventional ultrasonography suggested definite lesions in the breast;
2. In addition to conventional ultrasound, there is also enhanced MRI examination;
3. There are no contraindications for puncture biopsy, and pathological examination (cytology, histology) is planned to examine the patients with target lesions
4. Patients volunteered to participate in the study and signed informed consent.-

Exclusion Criteria

1. Those who are known to be allergic to ultrasound contrast agents;
2. The subject has a history of allergy to eggs or egg products (i.e. skin rash, dyspnea, swelling of the mouth or throat, hypotension or shock, etc.)
3. Arteriovenous (left and right) shunt patients in the heart and lungs
4. Patients with serious heart disease or serious lung disease
5. Patients who are pregnant, possibly pregnant or lactating
6. Patients who cannot receive contrast agent MRI
7. In addition, the investigator or the patient that the investigator considers not suitable to participate in this study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No